Q3 FY2026 · ended May 31, 2026 · Revenue $0, -100.0% YoY · Filed Jul 13, 2026
Lexaria Bioscience Corp. (LEXX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended May 31, 2026, it reported revenue of $0 and a net loss of $2.0 million. Free cash flow was -$1.6 million. As of May 31, 2026 it held $3.5 million in cash and investments and $86,714 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-1.99M
+47.4% vs year-ago quarter
Operating cash flow
$-1.64M
+54.4% vs year-ago quarter
Free cash flow
$-1.64M
+54.4% vs year-ago quarter
EPS
$-0.08
+61.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
24.79M
+26.7% vs year-ago quarter
Net cash
$3.41M
Q3 FY2026
Operating margin
-3973.2%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LEXX (Nasdaq)
- Fiscal year ends
- August 31
- Incorporated in
- NV
- Headquarters
- Kelowna, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1348362
- Former names
- Lexaria Corp. (until May 11, 2016); LEXARIA CORP. (until May 11, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 May 31, 2026 |
Q2 FY2026 Feb 28, 2026 |
Q1 FY2026 Nov 30, 2025 |
Q4 FY2025 Aug 31, 2025 |
Q3 FY2025 May 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $20,000 | $0 | $174,000 | $174,000 |
| Operating income | -$2.0M | -$1.5M | -$1.6M | -$2.7M | -$3.8M |
| Net income | -$2.0M | -$1.4M | -$1.6M | -$2.7M | -$3.8M |
| Diluted EPS | -$0.08 | -$0.06 | -$0.07 | -$0.14 | -$0.21 |
| Operating cash flow | -$1.6M | -$2.2M | -$984,098 | -$2.6M | -$3.6M |
| Free cash flow | -$1.6M | -$2.2M | -$984,098 | -$2.6M | -$3.6M |
| Total assets | $4.8M | $6.5M | $6.1M | $4.2M | $6.7M |
| Total liabilities | $437,091 | $276,997 | $1.5M | $1.6M | $1.6M |
| Stockholders' equity | $4.7M | $6.6M | $4.9M | $3.0M | $5.6M |
| Cash and investments | $3.5M | $5.1M | $4.3M | $371,214 | $4.6M |
| Total debt | $86,714 | $94,386 | $101,920 | $109,319 | $116,586 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 9, 2026 | Sep 7, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Other events
|
Aug 17, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 10, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 30, 2026 | Jul 29, 2026 |
| 10-Q | Quarterly report | Jul 13, 2026 | May 31, 2026 |
All 1000 Lexaria Bioscience Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.